Clinical Trial Update: Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating paliperidone palmitate for recently exacerbated schizophrenia has completed, providing an update on the study status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INVEGA SUSTENNA (PALIPERIDONE PALMITATE)

Snippet

Sponsor: Janssen-Cilag Farmaceutica Ltda. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED